Gary Chiang, Ph.D., and colleagues at Burnham Institute for Medical Research have elucidated how the stability of the REDD1 protein is regulated. The REDD1 protein is a critical inhibitor of the mTOR signaling pathway, which controls cell growth and proliferation.
Scientists at Burnham Institute for Medical Research have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues.
Magellan BioScience Group, Inc., a pioneer in innovative drug development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new medicines.
Scientists at Burnham Institute for Medical Research have discovered that specialized complex sugar molecules that anchor cells into place act as tumor suppressors in breast and prostate cancers.
Scientists at Burnham Institute for Medical Research have discovered that specific microRNAs (non-coding RNAs that interfere with gene expression) reduce HIV replication and infectivity in human T-cells. In particular, miR29 plays a key role in controlling the HIV life cycle. The study suggests that HIV may have co-opted this cellular defense mechanism to help the virus hide from the immune system and antiviral drugs.
Burnham Institute for Medical Research is continuing its bi-coastal expansion with the appointment of the director of the Metabolic Signaling and Disease Program in the Diabetes and Obesity Research Center at its campus in Lake Nona, located in Orlando, Florida.
Gregg Duester, Ph.D., professor of developmental biology at Burnham Institute for Medical Research, along with Xianling Zhao, Ph.D., and colleagues, have clarified the role that retinoic acid plays in limb development. The study showed that retinoic acid controls the development (or budding) of forelimbs, but not hindlimbs, and that retinoic acid is not responsible for patterning (or differentiation of the parts) of limbs.
Human monoclonal antibodies effective against bird and seasonal flu viruses; New leads for treating autoimmune diseases; "Sweet" insights to cancer metastasis; Maintaining the pipeline for blood flow; Custom-made drugs to fight inflammation; Keeping B lymphocyte proliferation in check; Engineering new heart cells; Link between diabetes drug and Alzheimer's disease; Potential drug target for Alzheimer's disease.
Six researchers from Burnham Institute for Medical Research will be presenting at the American Association for Cancer Research 100th Annual Meeting 2009.
Investigators at the Burnham Institute for Medical Research have developed a protocol to rapidly differentiate human embryonic stem cells (hESCs) into neural progenitor cells that may be ideal for transplantation. The research, conducted by Alexei Terskikh, Ph.D., and colleagues, outlines a method to create these committed neural precursor cells (C-NPCs) that is replicable, does not produce mutations in the cells and could be useful for clinical applications.
Burnham Institute for Medical Research at Lake Nona today announced that Stephen Gardell, Ph.D. has joined the Institute as Director of Translational Research Resources and Adjunct Associate Professor. Dr. Gardell's appointment is an indication of Burnham's intent to conduct basic medical research that can be quickly transferred from the laboratory to the clinic. Translational research, typically the domain of pharmaceutical laboratories, is moving downstream into not-for-profit research institutes to accelerate drug discovery and the development of diagnostic markers.
Scientists at Burnham Institute for Medical Research and the University of California San Diego School of Medicine have demonstrated in mice that transplanted pancreatic precursor cells are protected from the immune system when encapsulated in polytetrafluorethylene (PTFE). The study suggests a new approach to treating Type 1 diabetes.
Investigators at Burnham Institute for Medical Research have deciphered a large percentage of the total protein complement (proteome) in Schizosaccharomyces pombe (S. pombe) fission yeast.
Investigators at Burnham Institute for Medical Research have demonstrated that attacks on the mitochondrial protein Drp1 by the free radical nitric oxide"”which causes a chemical reaction called S-nitrosylation"”mediates neurodegeneration associated with Alzheimer's disease. Prior to this study, the mechanism by which beta-amyloid protein caused synaptic damage to neurons in Alzheimer's disease was unknown.
Investigators at Burnham Institute for Medical Research have learned that a protein called Shp2 plays a critical role in the pathways that control decisions for differentiation or self-renewal in both human embryonic stem cells (hESCs) and mouse embryonic stem cells (mESCs).
Researchers at the Dana-Farber Cancer Institute, Burnham Institute for Medical Research and the Centers for Disease Control and Prevention have identified human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses. These antibodies have the potential for use in combination with other treatments to prevent or treat certain types of avian and seasonal flu.
Taking clues from their stem cell research, investigators at the University of California San Diego and Burnham Institute for Medical Research have discovered that a signaling pathway involved in normal pancreatic development is also associated with type 2 diabetes.
Burnham signs agreement with Johnson & Johnson Pharmaceutical Research and Development LLC; develops a means to use search algorithms developed for the digital communications industry to identify drug combinations; identifies the molecular machinery that regulates DNA replication and the S-phase checkpoint; gets the first look at the molecular structure of the protein complex that controls apoptosis (programmed cell death).
San Diego philanthropist Conrad Prebys will donate $10 million to Burnham Institute for Medical Research to support the activities of Burnham's drug discovery center, which is part of the world's largest public drug discovery effort.
Researchers at the Burnham Institute for Medical Research have shown that search algorithms used in digital communications can help scientists identify effective multi-drug combinations.
Scientists at Burnham Institute for Medical Research have demonstrated important new roles for the protein kinase complex Cdc7/Dbf4 or Cdc7/Drf1 (Ddk) in monitoring damage control during DNA replication and reinitiating replication following DNA repair.
Scientists at Burnham Institute for Medical Research (Burnham) have determined the structure of the interactions between proteins that form the heart of the death inducing signaling complex (DISC), which is responsible for triggering apoptosis (programmed cell death).
Burnham Institute for Medical Research (Burnham) has announced the election of Peter Preuss to its board of trustees. Preuss, president and founder of The Preuss Foundation, brings expertise in business, philanthropy and science to Burnham.
1) Enzyme May Hold the Key to Muscular Dystrophy; 2) Microscopic Race for New Cures; 3) Nanoworms Make Tumors Squirm; 4) Choking Out Cancer.
HeadNorth Foundation has pledged $975,000 to Burnham Institute for Medical Research to support cutting-edge stem cell research.
Researchers at the Burnham Institute for Medical Research (Burnham) have shown in both fruit flies and humans that genes involved in embryonic heart development are also integral to adult heart function. The study, led by Rolf Bodmer, Ph.D., was published in Proceedings of National Academy of Sciences.
Burnham Institute for Medical Research (Burnham) announced the election of five new members to its board of trustees. These new trustees bring a wide variety of business, legal and philanthropic experience to Burnham.
Recent developments at the Burnham Institute for Medical Research. 1) $98 Million Dollar Grant Supports Drug Discovery; 2) Kill Cancer Cells with the Flip of a Switch; 3) What HIV Needs; 4) Burnham: the Next Generation; 5) Deep Diving for Drug Discovery
Burnham Institute announced that Dr. Stuart A. Lipton, professor and director of the Del E. Webb Neuroscience, Aging, and Stem Cell Research Center at Burnham, has been awarded $8 million from the NIH, over five years, to establish a Center for Neurodegeneration Science. The center will study potential environmental causes of Parkinson's disease.
Scientists at the Burnham Institute for Medical Research have shown that neural stem cell development may be linked to Autism. The study demonstrated that mice lacking the myocyte enhancer factor 2C protein in neural stem cells had smaller brains, fewer nerve cells and showed behaviors similar to those seen in humans with a form of autism known as Rett Syndrome.
Burnham Scientists have genetically programmed embryonic stem cells to become nerve cells when transplanted into the brain. The research, an important step toward developing new treatments for stroke, Alzheimer's, Parkinson's and other neurological conditions showed that mice afflicted by stroke showed tangible therapeutic improvement following transplantation of these cells.
Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.
Recent developments at the Burnham Institute - April 2008
Researchers at the Burnham Institute may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors.
The mission of the Cancer Center at Burnham Institute is to continue to bridge the gap between basic biological research and the anticancer drug discovery work carried out by pharmaceutical companies. These efforts have significantly benefited from the establishment of the San Diego Center for Chemical Genomics at Burnham, one of 10 collaborating centers known as the "Molecular Libraries Screening Centers Network".
Researchers at the Burnham Institute have discovered a new player in the development of a muscle disorder called sIBM. sIBM is the most common muscle disease among those over the age of 50, causing muscles to gradually weaken and waste away. This discovery provides a potential avenue for future diagnostic and therapeutic opportunities for this disease.
Burnham Institute announced that Daniel P. Kelly, M.D. will assume the position of Scientific Director of Burnham at Lake Nona in Orlando, Florida. In that capacity he will guide the scientific direction of Burnham's Orlando facility by forming several research programs related to diabetes, obesity, metabolism and heart disease.
$20 million donation creates collaboration between Burnham Institute for Medical Research and Sanford Health.
A collaborative group from the Burnham Institute in La Jolla, CA and in Japan, report that the herb rosemary contains an ingredient that fights off free radical damage in the brain. The active ingredient in rosemary, known as carnosic acid (CA), can protect the brain from stroke and neurodegeneration that is due to injurious chemical free radicals.
Scientists at the Burnham Institute for Medical Research have discovered how HIV/AIDS disrupts the normal replication of stem cells in the adult brain, preventing new nerve cells from forming. Results to be published in Cell Stem Cell report a novel molecular mechanism that inhibits stem cell proliferation and that could possibly be triggered in other neurodegenerative diseases.
The Burnham Institute for Medical Research ("Burnham") announced today creation of "The Donald Bren Presidential Chair" established with a $2.5 million gift from the Orange County philanthropist and businessman. Mr. Bren honors and supports the work of Dr. John C. Reed, Burnham's President and CEO. It is the first funded chair to support the work of a distinguished scientist at Burnham.
Researchers at Burnham Institute for Medical Research ("Burnham") have provided the first evidence that gamma-secretase, an enzyme key to the progression of Alzheimer's, acts as a tumor suppressor by altering the pathway of epidermal growth factor receptor (EGFR), a potential treatment target for cancer. Expedited to publication online by Proceedings of the National Academy of Sciences, these findings reveal a limitation of targeting gamma-secretase for treatment of Alzheimer's and potentially other diseases.
The California Institute for Regenerative Medicine (CIRM) announced today the award of $3.79 million to the Burnham Institute for Medical Research (Burnham) for development of a collaborative shared laboratory and expansion of the Institute's training courses in stem cell research. Burnham was one of 17 institutions receiving grants from CIRM for a total of more than $50 million.
The Burnham Institute for Medical Research (Burnham) has recruited Elizabeth Gianini as Vice President, External Relations for Burnham at Lake Nona, Orlando. Ms. Gianini will join Burnham on July 9 from her current position as Chief of Staff to Mayor Richard Crotty.
Burnham Institute for Medical Research (Burnham) announced today appointment of the first three recruits who will initiate operations in Orlando, Florida: director of medicinal chemistry, an assistant professor focusing on diabetes research, and vice president, finance and chief financial officer.
A team of researchers at the Burnham Institute for Medical Research ("Burnham") has been awarded $7.39 million from the National Institute of Child Health and Human Development of the National Institutes of Health. The funding will support a five-year, multi-project study entitled "Neuron-Glia Communication in Development."
The California Institute for Regenerative Medicine (CIRM) will fund comprehensive research projects directed by Dr. Mark Mercola and Dr. Stuart Lipton of the Burnham Institute for Medical Research (Burnham) with grants totaling more than $6 million.
Human embryonic stem cells (hESCs) can treat degenerative diseases safely and effectively, and do so by invoking multiple mechanisms. These were a few of a number of conclusions arrived at by an international collaboration led by Evan Y. Snyder, M.D., Ph.D., to be published in Nature Medicine.
The tiny Drosophila fruit fly may pave the way to new methods for studying and finding treatments for heart disease, the leading cause of death in industrialized countries, according to a collaborative study by the Burnham Institute for Medical Research, UC San Diego (UCSD) and the University of Michigan.
A protein known for its ability to "bridge" interactions between other cellular proteins may spur metastasis in breast cancer, the disease's deadliest stage, a study from Burnham Institute for Medical Research has found.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right